Clay Siegall is one of the co-founders of a company known as Seattle Genetics. The company was founded in 1998 and Siegall is the CEO, President and sits on the Board of Directors. The portfolio Seattle Genetics has developed is quite diverse. It is both preclinical and clinical candidates and targets autoimmune diseases and numerous types of cancer.
Seattle Genetics leads the industry in antibody technologies. The most prominent technology is an antibody drug conjugate called ADC. With Dr. Siegall’s guidance in raising capitol he has helped to secure over $300 million. This was through private and public financing including the original offering made in 2001. The company has also been a part of strategic collaborations. This includes an agreement with Genentech on an exclusive worldwide basis. The contract was for SGN-40 and the total value exceeded $860 million. There were also numerous collaborations with ADC including CuraGen, Progenics, Medimmune and Bayer. These collaborations came to a total of well over $65 million since the year 2001.
Before Dr. Siegall co-founded Seattle Genetics he worked with Bristol-Myers Squibb Pharmaceutical. He was with this Research Institute between the years of 1991 and 1997. Dr. Siegall worked with the National Institutes of Health as well as the National Cancer Institute between the years of 1988 and 1991. Dr. Siegall sits on the Board for Alder BioPharmaceuticals. This company is biotechnological and private. He is also on the Board of Directors for Biomedical Association in Washington. Dr. Siegall additionally sits on the Board for Fred Hutchinson Cancer Research.
Dr. Clay Siegall was schooled at the George Washington University where he received his Ph.D. in the field of genetics. He earned his B.S. in Zoology when he attened the University of Maryland.